**Introduction to Hydroxyethyl Starch (HES)** Hydroxyethyl starch (HES) is a synthetic colloid solution derived from natural starch, commonly used as a plasma volume expander in intravenous fluid therapy. It is designed to restore and maintain blood volume in cases of acute hypovolemia, such as during surgery, trauma, or severe hemorrhage. HES works by increasing oncotic pressure, drawing fluid into the bloodstream and improving circulation. Available in various molecular weights and substitution ratios, HES formulations are tailored for different clinical needs. While effective, its use has been debated due to potential risks, including kidney injury and coagulation impairment. Proper patient selection and dosing are essential to maximize benefits and minimize adverse effects.
Preparation Process: Hydroxyethyl starch (HES) is prepared by reacting starch (typically from corn or potatoes) with ethylene oxide under alkaline conditions. The process involves the following steps: 1. **Alkaline Treatment**: Starch is suspended in an alkaline solution (e.g., sodium hydroxide) to activate hydroxyl groups. 2. **Etherification**: Ethylene oxide is introduced, reacting with starch hydroxyl groups to form hydroxyethyl substituents. The degree of substitution (DS) is controlled by reaction time, temperature, and reagent ratios. 3. **Neutralization & Purification**: The product is neutralized, washed, and dried to remove residual reagents. 4. **Fractionation**: HES is hydrolyzed to desired molecular weights (e.g., 130–200 kDa for medical use) and sterilized. The final product is a white, water-soluble powder.
Usage Scenarios: Hydroxyethyl starch (HES) is a synthetic colloid used primarily as a plasma volume expander in intravenous fluid therapy. It helps restore blood volume in cases of acute hypovolemia, such as severe bleeding, surgery, or trauma, by increasing oncotic pressure and retaining fluid within the vascular system. HES solutions are derived from amylopectin and modified with hydroxyethyl groups to prolong their intravascular retention time. They are available in various molecular weights and substitution ratios, influencing their pharmacokinetics. However, HES use has declined due to safety concerns, including risks of kidney injury, coagulopathy, and mortality in critically ill patients, leading to restrictions in some countries.